Mariner
CMPX icon

Mariner’s Compass Therapeutics CMPX Stock Holding History

Mariner’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+172,821
New +$510K ﹤0.01% 2652
2025
Q2 		– Sell
-11,381
Closed -$21.6K – 3517
2025
Q1 		$21.6K Sell
11,381
-9,292
-45% -$24.7K ﹤0.01% 3371
2024
Q4 		$30K Buy
+20,673
New +$34.3K ﹤0.01% 3332

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mariner's CMPX Position: Q2 2026 in Review

Mariner opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 172,821 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #2652 among its holdings. This is a return to the name: Mariner previously reported a position in CMPX as recently as Q1 2025.

Mariner first reported a position in CMPX in Q4 2024 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Mariner held 172,821 shares of Compass Therapeutics worth $378K as of Q2 2026.
  • Compass Therapeutics was a new Mariner position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2652 holding.
  • Mariner first reported a position in Compass Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.